CareRx Corporation

CareRx Corporation

1.98
EUR
+0.05
(+2.59%)
132.11MMarket Cap
Nov 11Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
43.58
18.62
20.16
20.36
12.53
11.68
11.35
8
7.53
8.02
6.46
6.09
5.9
- -
Basic EPS, GAAP
-14.12
-7.91
5.78
-2.39
0.23
-3.29
-2.67
-0.9
-0.65
-0.72
-0.09
-0.07
0.42
- -
Free Cash Flow per Basic Share
1.68
1.65
2.99
-0.15
0.86
0.21
0.26
-0.09
- -
0.18
0.33
0.5
0.36
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.02
0.06
Book Value per Share
2.13
-4.59
1.78
0.3
1.95
-0.98
-1.41
0.46
1.78
1.26
1.36
1.36
1.74
1.73
Tangible Book Value per Share
-38.5
-30.21
-9.34
-11.18
-7.87
-6.67
-4.64
-3.06
-1.39
-1.15
-0.55
-0.32
0.17
0.14
Basic Weighted Avg Shares
6
7
8
8
10
10
11
20
35
48
57
60
63
63
Sales/Revenue/Turnover
281
135
161
167
122
119
125
162
263
382
371
367
370
- -
Operating Margin (%)
-3.26
-5.16
-3.63
2.04
2.04
-6.17
-2
-0.74
1.83
2
1.95
2.03
3.21
- -
Depreciation Expense
35
30
28
12
10
10
9
11
15
20
20
19
18
- -
Net Income, GAAP
-91
-57
46
-20
2
-34
-29
-18
-23
-34
-5
-5
26
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-32.4
-42.49
28.67
-11.76
1.87
-28.18
-23.52
-11.26
-8.65
-9
-1.46
-1.23
7.06
- -
Working Capital
18
31
178
-25
-81
-69
-49
2
42
25
3
- -
4
5
LT Debt
258
240
215
62
- -
- -
18
76
130
125
85
75
70
68
Total Equity
15
-34
15
3
20
-10
-20
11
82
64
82
84
110
110
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-167.87
- -
- -
-233.35
20.48
- -
- -
- -
-48.57
-46.82
-7.4
-5.43
26.97
- -

Capital Structure

CAD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
8
8
8
LT Borrowings
36
35
33
LT Finance Leases
34
36
35
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
63
63
64
Market Capitalization
236
225
214

Working Capital

CAD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
67
71
66
Cash, Cash Equivalents & STI
14
15
10
Accounts Receivable, Net
32
33
34
Inventories
18
19
19
Total Current Liabilities
63
64
61
Payables & Accruals
52
51
50
ST Debt
8
8
8
Deferred Revenue
1
1
1

Growth Rates

CAD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
96.09%
133.23%
30.01%
Free Cash Flow
455.55%
1,128%
-24.64%
Net Income, GAAP
-258.11%
-141.17%
-680.47%
Sales/Revenue/Turnover
11.37%
20.85%
0.96%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
90
92
93
92
367
2025
90
91
- -
96
370
2026
94
94
- -
- -
- -

Quarterly Earnings Per Share

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.01
-0.02
-0.01
-0.04
-0.07
2025
- -
0.01
- -
0.38
0.42
2026
0.02
0.01
- -
- -
- -

Quarterly Dividends Per Share

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
0.02
0.02
2026
0.02
0.02
- -
- -
- -

Company Description

CEO
Puneet Khanna
Full Time Employees
1,533
Sector
Health services
Industry
Medical/Nursing services
Address
320 Bay Street Toronto ON Canada M5H 4A6
IPO Date
Sep 4, 2002
Website
carerx.ca
Business
CareRx Corporation (TSX: CRRX) provides pharmacy services to seniors living in long-term care homes, retirement homes, assisted living facilities and group homes across Canada. Founded in 2001 and headquartered in Toronto, Ontario, the company operates a national network of pharmacy fulfillment centres in Ontario, Alberta, British Columbia, New Brunswick and Saskatchewan, serving approximately 91,000 residents through high-volume, cost-effective delivery of chronic medications and specialty clinical pharmacy solutions. Core offerings include multi-dose compliance packaging with automated preparation and verification technology for complex regimens; clinical reviews and consultations for physicians; staff education and training programs; regular medication deliveries; over-the-counter product access; and customized tools for medication management in long-term care, retirement, supportive housing and mental health/addictions settings. Recent developments encompass the initiation of a quarterly dividend in September 2025 to return capital to shareholders; renewal of a normal course issuer bid authorizing repurchase of up to 1.5 million common shares, or 2.5% of public float, through September 2026; and Q3 2025 results showing adjusted EBITDA of C$8.3 million, up 7% year-over-year, with an expanded 9.0% margin amid 2.5% growth in beds under care.

Company News

  • CareRx Announces New Credit Agreement with National Bank of Canada

  • CareRx Reports Results for the Second Quarter of 2026

  • CareRx Announces Q3 2026 Dividend

  • CareRx Reports Voting Results from Annual General Meeting of Shareholders

  • CareRx Announces Q2 2026 Dividend

  • CareRx Reports Results for The First Quarter of 2026

  • CareRx Corporation to Host First Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026 at 8:30 a.m. ET

  • CareRx Welcomes Stability in Long-Term Care Pharmacy Funding in Ontario

  • CareRx Corporation Announces Participation in the 2026 Bloom Burton & Co. Healthcare Investor Conference

  • CareRx Corporation (CRRX:CA) Q4 2025 Earnings Call Transcript

  • CareRx Announces Q1 2026 Dividend

  • CareRx Reports 2025 Year-End and Fourth Quarter Results

  • CareRx Corporation to Host Annual and Fourth Quarter 2025 Financial Results Conference Call on Thursday, March 5, 2026 at 8:30 a.m. ET

  • CareRx Announces Q4 2025 Dividend

  • CareRx Corporation (CRRX:CA) Q3 2025 Earnings Call Transcript

  • CareRx Reports Results for the Third Quarter of 2025

  • CareRx Corporation to Host Third Quarter 2025 Financial Results Conference Call on Tuesday, November 4, 2025 at 8:30 a.m. ET

  • CareRx Reports Results for the Second Quarter of 2025

  • CareRx Corporation to Host Second Quarter 2025 Financial Results Conference Call on Thursday, July 31, 2025 at 8:30 a.m. ET

  • CareRx Corporation to Host First Quarter 2025 Financial Results Conference Call on Wednesday, May 7, 2025 at 10:30 a.m. ET